Notably, homoharringtonine (HHT) has been approved by the FDA for the treatment of chronic myeloid leukemia, with mechanistic studies suggesting that HHT may affect the DNA epitope by direct targeting of SP1 and by inhibiting the SP1-mediated transcriptional regulation of the TET1 expression genome to exert antitumor effects (78). This evidence concerns the gene SP1 and chronic myelogenous leukemia, BCR-ABL1 positive.